Clinical trials: Measurable Residual Disease
Multiple Myeloma
Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma
The presence of minimal residual disease (MRD) is an important prognostic factor for multiple myeloma, while copy number variation (CNV) is a widely accepted biomarker used for multiple myeloma (MM).
- Trial name
- NCT06302699
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hepatocellular Carcinoma (HCC)
Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance
This is a prospective, observational, single-center study. The purpose of this study is to evaluate the efficacy of circulating tumor mitochondrial DNA (ct-mtDNA) in plasma as a biomarker for minimal residual disease (MRD)…
- Trial name
- CCGLC-015 (NCT06653062)
- Testing
- Plasma and Tumor Tissue Mitochondrial DNA (mtDNA) Mutation Analysis
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tongji Hospital
MDS, SCT
Individual Molecular MRD Monitoring for MDS Patients After Allo-SCT
This study aims to develop highly sensitive methods for early detection of relapse based on the patients unique mutations. Initially, a mutational screen is being performed.
- Conditions
- MDS, SCT, MRD
- Trial name
- NCT02872662
- Where
- 8 sites in Denmark, Norway and 1 more
- Volunteers
- 308 people
- Sponsor
- Nordic MDS Group
Biliary Tract Cancer
Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Biliary Tract Cancer Recurrence Surveillance
This is a prospective, observational, single-center study. The purpose of this study is to evaluate the efficacy of circulating tumor mitochondrial DNA (ct-mtDNA) in plasma as a biomarker for minimal residual disease (MRD)…
- Trial name
- CCGLC-016 (NCT06653127)
- Testing
- Plasma and Tumor Tissue Mitochondrial DNA (mtDNA) Mutation Analysis
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tongji Hospital
B-cell Acute Lymphoblastic Leukemia
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before…
- Trial name
- NCT03509961
- Testing
- NGS-MRD, Myeloablative allogeneic HCT with a non-TBI conditioning regimen
- Where
- 24 sites in United States
- Volunteers
- 95 people
- Sponsor
- Pediatric Transplantation & Cellular Therapy Consortium
Breast Neoplasms
Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast Cancer
This study evaluates the genomic profiles of breast cancer in a prospective and population-based manner. In the first phase, breast tumors are analyzed by whole transcriptome RNA-sequencing.
- Trial name
- SCAN-B (NCT02306096)
- Where
- 10 sites in Sweden
- Volunteers
- 20,000 people
- Sponsor
- Lund University
Biliary Tract Cancer
ctDNA Detection of MRD in Predicting Postoperative Recurrence in Biliary Tract Cancers：A Multicenter Prospective Trial
A substantial proporation of patients with biliary tract malignancies still experience disease recurrence after curative resection.
- Trial name
- NCT05743959
- Testing
- No intervention
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Multiple Myeloma
Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.
We propose to conduct an ancillary prospective evaluation of the impact of Dara-Len-Dex discontinuation after 2 years, on the persistence of MRD negativity in patients that were MRD negative at 2 years.
- Trial name
- MRD-CONFIRM (NCT05203003)
- Testing
- Assessment of MRD
- Where
- France
- Volunteers
- 260 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Myeloma
Multiple Myeloma Minimal Residual Disease
Three methods including flow cytometry, next generation sequencing and determination of circulating tumor cells will be performed at different time points in patients with previously undiagnosed multiple myeloma in order to…
- Trial name
- MMRD (NCT02627261)
- Testing
- blood samples and bone marrow aspirates will be collected
- Where
- 3 sites in France
- Volunteers
- 48 people
- Sponsor
- Hospices Civils de Lyon
Leukemia, Leukemia, Myeloid
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded.
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type
- Trial name
- CYNK001AML01 (NCT04310592)
- Testing
- CYNK-001
- Where
- 10 sites in United States
- Volunteers
- 27 people
- Sponsor
- Celularity Incorporated
NGS Monitor MRD
Next Generation Sequencing（NGS）Monitors Minimal Residual Disease（MRD）in Allo-PBSCT Patients
Objective: to evaluate the value of high-throughput next generation gene sequencing (NGS) in the detection of minimal residual disease (MRD) and recurrence after allogeneic transplantation. Overview of study design.
- Trial name
- NCT04126967
- Testing
- NGS patients
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xianmin Song, MD
Chronic Lymphocytic Leukemia (CLL)
Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)
This is a Phase 2, multicenter, open-label uncontrolled interventional study aimed a determining therapeutic benefits of the addition of ibrutinib to 12 months of venetoclax (single-agent for 6 months then combined with rituximab…
- Trial name
- VALUABLE (NCT04758975)
- Testing
- Venetoclax, Rituximab, Ibrutinib
- Where
- Italy
- Volunteers
- 55 people
- Sponsor
- Paolo Ghia
Lymphoma, B-Cell, Leukemia, B-Cell
CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation
The main purpose of this study is to explore the efficacy of CD19-targeted CAR-T cell therapy for minimal residual disease (MRD) in B-cell Malignancies after autologous stem cell transplantation.
- Conditions
- Lymphoma, B-Cell, Leukemia, B-Cell, Minimal Disease, Residual
- Trial name
- NCT03564977
- Testing
- CD19-targeted CAR-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Qingdao Central Hospital
Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma
This is a single-center, non-interventional, observational study that evaluates the correlation of circulating tumor DNA (ctDNA) testing to cancer relapse for participants with squamous cell carcinomas (HNC) of the head and neck…
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), Squamous Cell Carcinoma of Skin, Cutaneous Squamous Cell Carcinoma (CSCC)
- Trial name
- NCT06606028
- Testing
- Blood Specimen Collection, Tumor Tissue Collection, Medical Record Review
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- University of California, San Francisco
Acute Lymphoblastic Leukemia
Treatment for Ph-negative ALL for Adults up to 65 Years
The goal of this trial is to provide a protocol for treatment for adults with Ph-negative acute lymphoblastic leukemia (ALL) and to learn if this provides higher probability of survival than the previous one.
- Trial name
- LAL-2025 (NCT07443592)
- Testing
- Pediatric-type of chemotherapy (+blinatumomab for B-cell precursor ALL), Transplantation
- Where
- 95 sites in Spain
- Volunteers
- 330 people
- Sponsor
- PETHEMA Foundation
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
This study will find out whether people with CLL or SLL who have received treatment with venetoclax, either alone or in combination with another drug, and who are found to be MRD-negative, can stop treatment with venetoclax and…
- Trial name
- NCT04419519
- Testing
- Venetoclax monotherapy, Venetoclax with anti CD20 monoclonal antibody
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Lymphoblastic Leukemia
Treatment of Adult ALL With an MRD-directed Programme.
The study aims to optimize the concept of risk-oriented postremission consolidation therapy, by offering (i) standard consolidation-maintenance to patients at lowest risk of relapse as defined by MRD(Minimal Residual Disease)…
- Trial name
- NCT00358072
- Testing
- Postremission consolidation based on MRD status
- Where
- 15 sites in Italy
- Volunteers
- 280 people
- Sponsor
- Northern Italy Leukemia Group
CML (Chronic Myelogenous Leukemia)
Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI Treatment
The main purpose of the trial is to evaluate the safety and potential side effects of cell therapy vididencel in Chronic Myeloid Leukemia (CML) participants with measurable residual disease (MRD) unable to stop treatment with…
- Trial name
- NCT07651878
- Testing
- vididencel
- Where
- Norway
- Volunteers
- 24 people
- Sponsor
- Mendus
Precursor Lymphoid Neoplasms
Personalized Therapy of Precursor Lymphoid Neoplasms
The primary goal of this study by The Polish Adult Leukemia Group (PALG) is to verify if individual therapeutic approach taking into account biological and phenotypic differences as well as response at the level of minimal…
- Trial name
- NCT01665001
- Testing
- Treatment strategy: induction, consolidation, HSCT, maintenance
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice
Gastrointestinal Stromal Tumors
A Prospective Study on Predicting Recurrence Risk of Postoperative High-risk GISTs in NED State Based on MRD Detection Via Liquid Biopsy
The goal of this single-center, prospective, observational cohort study is to learn whether tumor-informed minimal residual disease (MRD) testing in blood can predict recurrence in 66 patients with high-risk gastrointestinal…
- Trial name
- NCT05867901
- Testing
- Tumor-Informed ctDNA-Based MRD Testing, Contrast-Enhanced CT
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Peking University People's Hospital